MindMed to Participate in September Investor Conferences
04 September 2024 - 9:00PM
Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or
“MindMed”), a clinical-stage biopharmaceutical company developing
novel product candidates to treat brain health disorders, today
announced that members of the Company’s management team will
participate in the following investor conferences:
- H.C. Wainwright 26th Annual Global Investment Conference
- Format: Panel
- Panel Title: Psychedelics in Psychiatry: Breaking New Ground in
Mood Disorders
- Date and Time: Tuesday, September 10, 2024 at 3:00 PM ET
- Location: New York, NY
- Baird’s 2024 Global Healthcare Conference
- Format: Fireside Chat
- Date and Time: Wednesday, September 11, 2024 at 12:15 PM
ET
- Location: New York, NY
- Webcast Link: Baird’s 2024 Global Healthcare Conference
- 2024 Cantor Global Healthcare Conference
- Format: Fireside Chat
- Date and Time: Tuesday, September, 17 at 10:20 AM ET
- Location: New York, NY
- Webcast Link: 2024 Cantor Global Healthcare Conference
Audio webcasts and replays of available presentations will be
accessible on MindMed’s Investor Relations website for up to 90
days following each event.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders. MindMed trades on NASDAQ under the symbol MNMD.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240904981833/en/
For Media: media@mindmed.co For Investors:
ir@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Dec 2024 to Jan 2025
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Jan 2024 to Jan 2025